Notable Analyst Rating Changes 07/03: (ZION) (LEAP) (AN) Upgraded; (MJN) (ACCO) (AA) Downgraded
Tweet
Share
E-mail
Get Alerts ZION Hot Sheet
Price: $41.27 -2.13%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.1%
Revenue Growth %: -100.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.1%
Revenue Growth %: -100.0%
Join SI Premium – FREE
UPGRADES
Citi boosts Zions Bancorp (Nasdaq: ZION) from Neutral to Buy.
Macquarie moves Leap Wireless (Nasdaq: LEAP) from Underperform to Neutral, moving its price target from $4.50 up to $7.50. Click Here for more color.
Credit Suisse raises AutoNation Inc. (NYSE: AN) from Neutral to Outperform.
UBS upgrades ARM Holdings (Nasdaq: ARMH) from Neutral to Buy.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
Wells Fargo lowers Mead Johnson Nutrition (NYSE: MJN) from Outperform to Market Perform, moving its price target from $88 down to $77. Click Here for more color.
Credit Suisse trims ACCO Brands (NYSE: ACCO) from Outperform to Neutral.
JPMorgan downgraded Alcoa (NYSE: AA) from Buy to Neutral, while its $12 price target was lowered to a December 2014 target of $9. Click Here for more color.
BofA/Merrill Lynch reduces Overstock.com (Nasdaq: OSTK) from Buy to Underperform, moving its price target from $20 to $23. Click Here for more color.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
Goldman Sachs reinstates Best Buy (NYSE: BBY) at Buy rating and a price target of $34. Click Here for more color.
RBC Capital initiates Ecolab Inc. (NYSE: ECL) at Outperform and $97 target.
Guggenheim starts Celldex Therapeutics (Nasdaq: CLDX) with a Buy and price target of $24.
Needham & Company begins 21st Century Fox (Nasdaq: FOXA) with a Buy rating and $36 price target.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Citi boosts Zions Bancorp (Nasdaq: ZION) from Neutral to Buy.
Macquarie moves Leap Wireless (Nasdaq: LEAP) from Underperform to Neutral, moving its price target from $4.50 up to $7.50. Click Here for more color.
Credit Suisse raises AutoNation Inc. (NYSE: AN) from Neutral to Outperform.
UBS upgrades ARM Holdings (Nasdaq: ARMH) from Neutral to Buy.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
Wells Fargo lowers Mead Johnson Nutrition (NYSE: MJN) from Outperform to Market Perform, moving its price target from $88 down to $77. Click Here for more color.
Credit Suisse trims ACCO Brands (NYSE: ACCO) from Outperform to Neutral.
JPMorgan downgraded Alcoa (NYSE: AA) from Buy to Neutral, while its $12 price target was lowered to a December 2014 target of $9. Click Here for more color.
BofA/Merrill Lynch reduces Overstock.com (Nasdaq: OSTK) from Buy to Underperform, moving its price target from $20 to $23. Click Here for more color.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
Goldman Sachs reinstates Best Buy (NYSE: BBY) at Buy rating and a price target of $34. Click Here for more color.
RBC Capital initiates Ecolab Inc. (NYSE: ECL) at Outperform and $97 target.
Guggenheim starts Celldex Therapeutics (Nasdaq: CLDX) with a Buy and price target of $24.
Needham & Company begins 21st Century Fox (Nasdaq: FOXA) with a Buy rating and $36 price target.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 10 analysts discuss Meta Platforms (META) stock after earnings selloff
- OncoCyte Corp (OCX) PT Raised to $4.25 at Needham
- Day One Biopharmaceuticals (DAWN) PT Raised to $33 at Needham
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Credit Suisse, UBS, JPMorgan, Citi, Needham & Company, RBC Capital, Notable Analyst Rating Changes, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
